Sartorius Ag · XETR:SRT
Sartorius — Sartorius Stedim Biotech — Investor Presentation (2026)
17 slides from Sartorius's investor presentation, 2026
Slide 1: Simplifying Progress: This is Sartorius Stedim Biotech
Simplifying Progress This is Sartorius Stedim Biotech 2026
Slide 2: Our purpose: Better health for more people
Our purpose: Better health for more people We empower scientists and engineers to simplify and Mission accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine. 2
Slide 3: Sartorius Stedim Biotech in 2025 numbers
Sartorius Stedim Biotech in 2025 numbers ~€3.0bn Sales revenue 30.8% Profit margin1 10,200+ Employees ~€390mn 50+ Investments Locations worldwide 1 Underlying EBITDA margin 3
Slide 4: More than 10,200 employees united by strong values
More than 10,200 employees united by strong values 96 Nationalities Sustainability Openness Enjoyment Growing profitably and Driving change Working in an energetic acting responsibly towards and progress and rewarding Younger than all stakeholders internally and externally environment 54% 40 years 4
Slide 5: What are biopharmaceuticals?
What are biopharmaceuticals? Chemical drugs Advantages of Aspirin biopharmaceuticals (C9H8O4) Target only diseased cells Administered Fewer side effects Small, simple Obtained via molecules chemical synthesis in various ways Allow first-time or improved treatment of Biopharmaceuticals illnesse
Slide 6: The promises of biologics: From established to new concepts
The promises of biologics: From established to new concepts Breakthroughs at an ever-increasing pace and new forms of treatment offer hope for patients 1796 1818 1982 1986 2012 / 2017 2020 2023 Blood Recombinant Monoclonal Cell & gene mRNA CRISPR Vaccines products proteins antibodies therapies vacci
Slide 7: Many biotech medications are highly effective, but very expensive
Many biotech medications are highly effective, but very expensive Rheumatism Blood cancer Leukodystrophy Monoclonal antibodies CAR-T cell therapy Gene therapy ~€12,000 ~€240,000 ~$4.25mn Annual cost of treatment in GER Cost per treatment in Europe Cost per treatment in the USA 7
Slide 8: The manufacture of biologics is complex
The manufacture of biologics is complex 8
Slide 9: Providing technologies to increase productivity in bioprocessing
Providing technologies to increase productivity in bioprocessing Our ambition Our solutions More efficient bioprocessing Technologies for all phases of drug manufacturing Set up safe and flexible processes Increase resource and material efficiency Media & reagents Bioreactors & fermenters Reduce inv
Slide 10: Offering integrated end-to-end manufacturing solutions
Offering integrated end-to-end manufacturing solutions Upstream Production of the desired drug Cell culture media & Seed Scale-up Production preparation cultivation Downstream Isolation and filling of the desired drug Final Cryo- Sterile Concen- Virus clearance Chroma- Clarification & filling preser
Slide 11: Pioneering the industry: New platform supports transition to continuous bioprocesses
Pioneering the industry: New platform supports transition from batch to continuous bioprocesses Today Future Pionic® Cooperation with Batch- Continuous Production Production Lower production costs Higher productivity Shorter time-to-market Spin Dual Fewer CO2-emissions 2025 2026 11
Slide 12: Cell and gene therapies: New modalities, new challenges
Cell and gene therapies: New modalities, new challenges Next generation biopharmaceuticals Enabling CGT: High need for innovation Viral Vectors mRNA Stem Cells Exosomes DNA New Vaccines Robustness of production process Yields, productivity, cost-per-dose Innovative treatments for patients Time-to-ma
Slide 13: Extensive technology platform for cell and gene therapy applications
Extensive technology platform for cell and gene therapy applications Up & downstream solutions Biological CellGenix Xell Albumedix Polyplus Industries Cell line development, Cell culture Growth factors Media and Recombinant Transfection plasmid design & media and cytokines supplements Albumin reagen
Slide 14: Ongoing investment in innovation, growth and resilience
Ongoing investment in innovation, growth and resilience Songdo, South Korea Sterile consumables, labs Göttingen, Germany Nottingham, UK Filter Cell culture components Freiburg, Germany Bielefeld, Germany Cell culture components Media 2025 €390mn 13.3 % Investment Investment ratio 14
Slide 15: Strong financial track record; profitable growth
Strong financial track record; profitable growth High volatility during and post pandemic Ø Annual growth 3700 3500 ~13% 2015-2025 69.5 67.5 65.5 ~€3.0bn 3300 63.5 3100 61.5 2900 59.5 57.5 2700 55.5 2500 53.5 2300 51.5 49.5 2100 47.5 1900 45.5 1700 43.5 41.5 1500 1300 35.8 35.0 39.5 37.5 1100 ~€880m
Slide 16: Ambitious mid-term climate agenda in line with Paris Climate Agreement
Ambitious mid-term climate agenda in line with Paris Climate Agreement 2030 mid-term ambitions 2045 long-term ambition Net-zero Scope 1 & 2 Scope 3 emissions 42% 51.6% Reduction of GHG emissions Reduction of GHG emissions relative compared to 2022 to value added1 compared to 2022 Use of renewable en
Slide 17: Simplifying Progress
Simplifying Progress Sartorius Stedim Biotech Zone Industrielle les Paluds 510 avenue de Jouques 13400 Aubagne France
Sartorius Stedim Biotech — Investor Presentation (2026) on 6ix